In direct-compression tablet manufacture, the Yudu Zhike Powder Veterinary Grade API is routed through particle size preconditioning because dose uniformity is governed by USP <905> and tablet friability by USP <1216>. The addition ratio is fixed by the approved dose and tablet core mass: for a 300 mg tablet carrying a 15 mg dose, the arithmetic incorporation is 5.0% w/w; for a 120 mg tablet with the same dose, it is 12.5% w/w. The milled PSD is matched to the carrier system because if the API D90 exceeds 180 µm, segregation in the press feed frame can raise mass RSD above 5.0% and generate superpotent cores. A cone mill fitted with a 0.610 mm grater screen is operated at 1,500–2,500 rpm to bring the API D90 below 150 µm. A 600 L bin blender then charges the API with lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate; blend uniformity is sampled at 10 points and the RSD limit is 3.0%. Rotary tablet presses with B-tooling apply precompression at 3.0 kN and main compression at 10–16 kN, with in-process hardness held at 50–80 N and friability below 1.0%. Compression is performed in a dehumidified suite at 20–25°C and 35–45% RH. Film coating with an aqueous hydroxypropyl methylcellulose system is run at pan speed 6–10 rpm, inlet air 55–65°C, and product temperature 35–40°C. Terminal product types include film-coated scored tablets, chewable tablets with palatability agents, and uncoated tablets for direct oral administration. The operational boundary is moisture: if dynamic vapor sorption shows mass gain above 2.0% at 60% RH within 4 h, pre-drying at 40°C for not more than 2 h is required and the compression suite must remain below 40% RH. Direct compression is unsuitable when the API is cohesive and the bulk density ratio between API and carrier is below 0.7 or above 1.4 because blend uniformity becomes batch-to-batch variable. Compliance is anchored to 21 CFR 211.110, VICH GL18, and Ph. Eur. 2.9.40.

Does Sterile Filtration of the Veterinary Injection Require pH Buffer Adjustment Before Terminal Processing?

Sterile solutions of the veterinary API intended for parenteral administration in cattle or swine are compounded by dissolving the powder in Water for Injection under nitrogen sparging. The addition ratio is expressed on a w/v basis and derived from the approved dose divided by the dose volume: a 100 mg/mL formulation is 10.0% w/v and is appropriate only when the dose volume is limited by injection site tolerance. If the dose is 2 mg/kg and the product is injected at 1 mL per 25 kg body weight, the concentration becomes 50 mg/mL, or 5.0% w/v. Compounding includes pH adjustment with dilute hydrochloric acid or sodium hydroxide to a target pH of 4.0–7.0, tonicity adjustment with sodium chloride to 280–320 mOsm/kg, and pre-filtration through a 0.45 µm PVDF membrane followed by 0.22 µm sterilizing-grade filtration. The downstream production process is conducted in a Grade A environment with Grade B background under EU GMP Annex 1; filter integrity is tested before and after filling by bubble point or diffusive flow within the filter manufacturer’s specified limits. Terminal sterilization at 121°C for 15 min may be applied only if forced degradation data show no more than 0.5% degradation; otherwise, aseptic filtration is mandatory. Filling lines use peristaltic pumps into Type I glass vials of 10 mL, 50 mL, or 100 mL, with fill volumes checked against USP <1>. Terminal product types include multi-dose vials with benzyl alcohol as preservative at 1.0–2.0% v/v, single-dose vials, and 100 mL infusion bottles. For food-producing species, the withdrawal period is fixed by residue depletion data submitted under the applicable marketing authorisation and the residue limits referenced in Commission Regulation 37/2010. The critical process boundary is oxidation: if dissolved oxygen in solution exceeds 2.0 mg/L before filling, headspace oxygen is flushed with nitrogen to below 5.0% v/v. The solution must not be combined with strong alkalis or oxidising agents; for a weak base salt, a pH shift above 8.0 can precipitate the free base and raise subvisible particle counts above the limits in Ph. Eur. 2.9.19. Compliance rests on USP <71>, USP <85>, and 21 CFR 210/211 aseptic processing controls.

When a water-soluble sachet is reconstituted in poultry drinking water, the process risk is less a mixing problem than a hydrate stability problem, because the effervescent carrier system can pre-react if residual moisture is not controlled. The API addition ratio in the bulk powder is set by the desired stock solution concentration and the dosing pump ratio: a stock solution of 100 g/L delivered through a 1:50 proportioner yields a final drinking water concentration of 2.0 g/L. The dry blend is formulated with lactose monohydrate, citric acid, sodium bicarbonate, and povidone; if the API is potent, the addition ratio may be 5.0% w/w, whereas less potent APIs may occupy up to 40.0% w/w. Production is carried out in a ribbon mixer with an effective volume of 500 L and a rotor speed of 15–20 rpm; the citric acid and sodium bicarbonate are pre-sieved through a 0.500 mm screen and kept below 0.5% LOD before combining. The blended powder is filled into laminated aluminium sachets of 100 g, 500 g, and 1 kg under nitrogen sealing; seal integrity is verified by vacuum leak testing. At the farm level, the stock solution is drawn through a 50 µm in-line filter to prevent undissolved particles from blocking nipple drinkers. Hard water with calcium carbonate equivalents above 150 mg/L can reduce solubility by forming insoluble calcium salts; a compatibility test using the target farm water is required because published data for this specific configuration is limited. Free chlorine above 2.0 ppm may also degrade oxidisable functional groups; if the water supply exceeds this level, the solution should be prepared in a bypass tank with sodium thiosulfate at a stoichiometric dosage determined by chlorine demand. Terminal product types include single-dose sachets for 100 L, 500 L, and 1,000 L drinking water systems. Compliance is anchored to EU 183/2005 on feed hygiene, ISO 6497:2005 for sampling of animal feeding stuffs, and the general in-process controls of 21 CFR 211.110.

When a Medicated Premix Is Diluted 1:100 in Finished Feed, Which Mixer Variables Control Carryover?

Medicated feed premix operations begin with the calculation of the API addition ratio from the final feed inclusion rate. If the target finished feed concentration is 200 g/ton and the premix is dosed at 10 kg/ton of finished feed, the premix must contain 2.0% w/w API; if the target is 1,000 g/ton under the same 1:100 dilution, the premix must be 10.0% w/w API. The production process uses geometric dilution in a horizontal batch ribbon mixer of 1,000 L working volume at 20–30 rpm. The first pass blends the API with 1 part of carrier for 10 min, then 3 parts for 10 min, then the remaining carrier for 15 min. Batch-to-batch variance is measured by sampling 10 spatially distributed points with a thief sampler; the assay RSD must not exceed 5.0%. If the RSD exceeds this threshold, the mixer is run for an additional 5 min, but over-mixing can generate fines and promote segregation. The carrier system is selected by bulk density matching to the API; if the API bulk density is 0.45 g/mL and the carrier is 0.60 g/mL, the ratio is 0.75, within the preferred range of 0.7–1.4. Terminal product types include 25 kg multi-wall paper bags and flexible intermediate bulk containers with polyethylene liners. At the feed mill, if pelleting conditioning temperature exceeds 75°C and the API is heat-labile, the premix should be applied post-pelleting as a liquid suspension or top-dressed after cooling. Carryover is controlled by flush batches of ground corn or dedicated production lines; the maximum carryover is defined by the target species maximum residue limit. The critical limitation is electrostatic charge in milling environments below 30% RH, which can cause the API to adhere to mixer walls and reduce assay recovery by more than 3.0%; wall scraping and equipment grounding are required. Compliance is anchored to EU 183/2005, ISO 6497:2005, and GMP+ BA2 feed safety assurance requirements.

The following systematic matrix links premix addition ratio to final feed concentration and mixer uniformity limits.

For hard gelatin capsule filling, the veterinary API imposes a discrete set of flow constraints because the powder’s cohesion and aeration characteristics determine fill weight distribution. The addition ratio is derived from the capsule fill mass and the approved dose: a 200 mg fill in a size 3 capsule carrying a 25 mg dose contains 12.5% w/w API. If the dose is 75 mg in a size 1 capsule with 400 mg fill, the addition ratio is 18.75% w/w. The production process includes passing the API and lactose monohydrate through a 0.500 mm sieve, blending in a 300 L V-blender at 15 rpm for 20 min, and filling on a rotary tamping-pin machine with powder bed depth of 15 mm and pin compression 18–22 mm. Fill weight variability is maintained at RSD below 2.0%. If the powder’s flow function coefficient is below 4.0, colloidal silicon dioxide is added at 0.5–1.0% w/w; if it is above 10.0, direct encapsulation without granulation is usually viable. The capsule shells are dedusted and passed through a metal detector with sensitivity set to reject ferrous particles above 0.5 mm. Dissolution method development starts with USP <711> apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid as a discriminatory starting condition; the acceptance criterion is taken from the approved product monograph. Terminal product types include size 1 and size 3 hard gelatin capsules, HPMC capsules for vegetarian lines, and unit-dose blister packs. The critical limitation is hygroscopicity: if the blended fill gains more than 2.0% moisture at 60% RH, capsule shells may become brittle and fill may clump; desiccant sachets are added to the primary packaging when the stability data justify it. Magnesium stearate must not exceed 1.0% w/w because higher concentrations delay dissolution and increase RSD variability. Compliance is supported by USP <905>, Ph. Eur. 2.9.1, and Ph. Eur. 2.9.3.

The following compliance checklist maps the six production routes to their controlling standards and process parameters.

Granulation Endpoint Metrics for Oral Top-Dress Powders

Because the top-dress granule must disintegrate in the oral cavity or upper gastrointestinal tract, wet granulation of the veterinary powder is controlled by torque rise and final loss-on-drying rather than by fixed massing time. The API addition ratio in the granule is set by the field dose: a 5 g top-dress dose carrying 1 g API is 20.0% w/w, while a 10 g dose carrying 1 g API is 10.0% w/w. The downstream process uses a high-shear granulator with impeller speed 250–350 rpm and chopper speed 1,500–2,500 rpm; dry mixing lasts 3 min, binder addition is completed over 2–3 min, and wet massing is continued until the torque increases by 25–40% over the dry-mix baseline. The wet mass is transferred to a fluid bed dryer with inlet air 60–70°C, product temperature 35–45°C, and final LOD 1.5–2.5%. Granules are sieved through 0.500 mm and 1.400 mm screens; the target fraction between these screens should represent at least 70% of yield. Terminal product types include 500 g and 1 kg foil-lined sachets for oral top-dress administration to calves, foals, and pigs. The primary process conflict is over-granulation: excessive chopper time above 5 min produces dense granules that slow disintegration and lower dissolution. Under-granulation, with torque increase below 25%, produces friable granules and generates fines below 10% of yield, which causes dust and segregation in the sachet. If the residual moisture exceeds 2.5%, caking and microbial proliferation become probable; the drying curve should be monitored by near-infrared or loss-on-drying every 10 min after the product temperature reaches 35°C. The granulation system must not be combined with hygroscopic binders above 5.0% w/w unless the sachet is double-foil sealed. Compliance is anchored to VICH GL18 for residual solvent control, 21 CFR 211.110 for in-process sampling, and Ph. Eur. 2.9.40 for uniformity of dosage units.